首页> 外文期刊>Clinical and experimental hypertension: CEH >Combination of angiotensin II receptor antagonist with calcium channel blocker or diuretic as antihypertensive therapy for patients with chronic kidney disease.
【24h】

Combination of angiotensin II receptor antagonist with calcium channel blocker or diuretic as antihypertensive therapy for patients with chronic kidney disease.

机译:血管紧张素II受体拮抗剂与钙通道阻滞剂或利尿剂的组合作为慢性肾脏疾病患者的降压治疗。

获取原文
获取原文并翻译 | 示例
           

摘要

We compared treatment with an angiotensin II receptor antagonist (ARB) and a calcium channel blocker (CCB) combination and a fixed-dose ARB and thiazide diuretic in 18 chronic kidney disease (CKD) patients. A randomized crossover study was performed using a fixed-dose combination of losartan-hydrochlorothiazide or losartan combined with controlled-release nifedipine. Both systolic blood pressure (SBP) and diastolic blood pressures (DBPs) were lower during the nifedipine period than during the diuretic period. No significant difference was observed in urinary albumin excretion, but the estimated glomerular filtration rate was higher in the nifedipine than in the diuretic period. Serum uric acid and low-density lipoprotein cholesterol were higher in the diuretic than in the nifedipine period. A significantly low cardio-ankle vascular index, an index of arterial wall stiffness, was observed in the nifedipine period. A combination of ARB and a controlled-release nifedipine at 20-40 mg used showed a superior antihypertensive effect in CKD patients compared to a fixed-dose combination of losartan 50 mg-hydrochlorothiazide 12.5 mg in terms of blood control. The former combination is considered advantageous for maintaining renal function and artery wall elasticity without influencing uric acid or lipid metabolism.
机译:我们比较了在18例慢性肾脏病(CKD)患者中使用血管紧张素II受体拮抗剂(ARB)和钙通道阻滞剂(CCB)组合以及固定剂量的ARB和噻嗪利尿剂的治疗效果。使用氯沙坦-氢氯噻嗪或氯沙坦的固定剂量组合与控释硝苯地平联合进行了一项随机交叉研究。硝苯地平期间的收缩压(SBP)和舒张压(DBPs)均低于利尿期。尿白蛋白排泄没有观察到显着差异,但是硝苯地平估计的肾小球滤过率高于利尿期。利尿剂中的血尿酸和低密度脂蛋白胆固醇高于硝苯地平时期。在硝苯地平时期观察到明显低的心踝血管指数,即动脉壁僵硬度指数。与固定剂量的氯沙坦50 mg-氢氯噻嗪12.5 mg的固定剂量组合相比,所用的ARB和20-40 mg控释硝苯地平的组合在CKD患者中显示出优异的降压作用。前者被认为有利于在不影响尿酸或脂质代谢的情况下维持肾功能和动脉壁弹性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号